Brokerages Set NewAmsterdam Pharma (NASDAQ:NAMS) PT at $33.80

NewAmsterdam Pharma (NASDAQ:NAMS) has been given a consensus rating of “Buy” by the six brokerages that are presently covering the company, Marketbeat.com reports. Six analysts have rated the stock with a buy recommendation. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $33.80.

NAMS has been the subject of a number of recent analyst reports. Needham & Company LLC reiterated a “buy” rating and issued a $36.00 price target on shares of NewAmsterdam Pharma in a research report on Thursday, November 21st. Royal Bank of Canada reiterated an “outperform” rating and issued a $31.00 price target on shares of NewAmsterdam Pharma in a research report on Thursday, September 5th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $37.00 price target on shares of NewAmsterdam Pharma in a research report on Monday, September 23rd.

Insiders Place Their Bets

In related news, CAO Louise Frederika Kooij sold 45,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $15.72, for a total value of $707,400.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Nap B.V. Forgrowth sold 8,530 shares of the business’s stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $25.02, for a total value of $213,420.60. Following the completion of the sale, the insider now directly owns 11,812,033 shares of the company’s stock, valued at approximately $295,537,065.66. The trade was a 0.07 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 86,803 shares of company stock worth $1,755,307. 19.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On NewAmsterdam Pharma

Several large investors have recently made changes to their positions in the company. Geode Capital Management LLC lifted its holdings in NewAmsterdam Pharma by 1.6% in the 3rd quarter. Geode Capital Management LLC now owns 86,322 shares of the company’s stock worth $1,433,000 after purchasing an additional 1,399 shares during the last quarter. Banque Cantonale Vaudoise acquired a new stake in NewAmsterdam Pharma in the 2nd quarter worth approximately $38,000. Quarry LP lifted its holdings in NewAmsterdam Pharma by 2,469.2% in the 3rd quarter. Quarry LP now owns 6,500 shares of the company’s stock worth $108,000 after purchasing an additional 6,247 shares during the last quarter. Barclays PLC lifted its holdings in NewAmsterdam Pharma by 1,813.4% in the 3rd quarter. Barclays PLC now owns 7,596 shares of the company’s stock worth $126,000 after purchasing an additional 7,199 shares during the last quarter. Finally, Bellevue Group AG acquired a new stake in NewAmsterdam Pharma in the 3rd quarter worth approximately $128,000. Institutional investors own 89.89% of the company’s stock.

NewAmsterdam Pharma Stock Up 1.7 %

NASDAQ:NAMS opened at $19.98 on Friday. The business’s 50-day moving average price is $19.63 and its 200 day moving average price is $18.56. NewAmsterdam Pharma has a 52-week low of $8.90 and a 52-week high of $26.35.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.